ETrade Capital Management’s iBio IBIO Stock Holding History

ETrade Capital Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25	Closed	-$28K	–	916
2020 Q2	$28K	Buy	+25	New	+$16.3K	﹤0.01%	831

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

ETrade Capital Management's IBIO Position: Q3 2020 in Review

ETrade Capital Management sold out of iBio (IBIO) in Q3 2020, closing a stake of 25 shares — an estimated $28K sold.

ETrade Capital Management first reported a position in IBIO in Q2 2020 and held it in 1 quarter. The position peaked at $28K in Q2 2020. 77 funds tracked by Wall St. Rank hold IBIO as of Q3 2020.

ETrade Capital Management reported no remaining iBio position as of Q3 2020 after selling out during the quarter.
ETrade Capital Management sold 25 iBio shares in Q3 2020, an estimated $28K.
ETrade Capital Management first reported a position in iBio in Q2 2020 and held it in 1 quarter.
ETrade Capital Management's iBio position peaked at $28K in Q2 2020.
77 funds tracked by Wall St. Rank held iBio as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.